Ricardo Mouzo Mirco
Quick facts
Phase 3 pipeline
- Paricalcitol, atorvastatin · Nephrology / Cardiovascular
This combination uses paricalcitol to activate vitamin D receptors for mineral metabolism regulation and atorvastatin to inhibit HMG-CoA reductase for cholesterol lowering.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: